SVB Securities analyst Jonathan Chang maintained a Buy rating on Immatics (IMTX – Research Report) on May 2 and set a price target of $16.00. The company’s shares opened today at $9.69.
According to TipRanks, Chang is an analyst with an average return of -15.9% and a 23.08% success rate. Chang covers the Healthcare sector, focusing on stocks such as ImmunoGen, Kura Oncology, and Mersana Therapeutics.
Currently, the analyst consensus on Immatics is a Strong Buy with an average price target of $17.67, representing an 82.35% upside. In a report released on May 3, Mizuho Securities also reiterated a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
IMTX market cap is currently $742.2M and has a P/E ratio of 20.03.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
Read More on IMTX:
- Immatics Soars after Positive Clinical Update
- Immatics reports interim clinical data from ongoing Phase 1b Cohort A
- Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
- Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
- TipRanks ‘Perfect 10’ List: These 2 Top-Rated Stocks Could Be Long-Term Winners
